About Artios Pharma

Artios develops precision cancer medicines by exploiting DNA Damage Response pathways. Founded by the scientists who invented the blockbuster PARP inhibitor Lynparza, the company applies decades of DDR expertise to a pipeline of novel therapeutics. The lead programme, alnodesertib, is a first in class ATR inhibitor in late stage trials for platinum resistant ovarian cancer and other high unmet need cancers. Operating from Cambridge and New York, Artios is backed by leading investors including SV Health Investors and RA Capital. The company combines translational science with biomarker driven development to identify patients most likely to benefit, aiming to deliver meaningful survival gains where traditional treatments fall short.